At 250 sites world wide the Eurolyser smart 546 was selected to perform patient near testing for an open-label, multicentre, randomised, 3-arm study. It is to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease.

“We are very proud of being part of such an important study. This is jet another proof ot the reliability and flexibility of the Eurolyser smart point of care system” says Gerhard Bonecker, CEO of Eurolyser Diagnostica.

Besides clincal studies, the unique platform is used by general practitioners, diabetes centers, angiologists, emgergency labs, cardiologists, gynecologists, pediatricians, blood donation centers and anti-aging physicians. Tests available for the instrument include CRP, hsCRP, INR (PT), Homocystein, Lipoprotein(a), D-Dimer, µAlbumin, Haemoglobin and – as mentioned above -Ferritin.

“This easy-to-operate analyzer is a worthwhile investment for every user, thanks to its great flexibility and constantly expanding test protfolio” remarks Mike Gruber, MD of Eurolyser Diagnostica. “We are about to launch a fully quantitative FOB (faecal occult blood) test, which will further enhance the test menue” he ads with a smile